Delcath System Inc. NASDAQ DCTH

Delcath is a development stage specialty pharmaceutical and medical device company focused on oncology. We are developing a proprietary system for Chemosaturation Therapy that is designed to administer high doses of chemotherapeutic agents to a diseased organ or a region of the body while protecting the patient from potential systemic side effects.

The Chemosaturation Therapy system is designed to be a repeatable, minimally invasive procedure that isolates the blood flow of the targeted organ, saturates the isolated organ with therapeutic agent, and then filters out toxic levels of the drug before returning it to the patient.

The Delcath Chemosaturation system is not currently approved by the FDA or any other regulatory body, and it cannot be marketed in the United States or elsewhere without regulatory approval.